Song Shanshan, Wang Baosheng, Gu Shuailin, Li Xiaocheng, Sun Shaolong
Department of Pancreas and Endocrine Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Oncol Lett. 2017 Dec;14(6):7849-7861. doi: 10.3892/ol.2017.7218. Epub 2017 Oct 18.
Aberrant expression of Beclin 1 and B-cell lymphoma-2 (Bcl-2) has been identified in a variety of human tumors; however, little information is available for pancreatic neoplasms. The present study analyzed the expression of Beclin 1 and Bcl-2 in pancreatic ductal adenocarcinoma (PDAC) and solid pseudopapillary neoplasm (SPN) of the pancreas, and evaluated their prognostic significance for PDAC. The present study included 117 PDAC, 43 SPN and 32 chronic pancreatitis (CP) cases. Levels of Beclin 1 and Bcl-2 expression were evaluated semiquantitatively by immunohistochemistry, and their correlation with the survival of patients with PDAC was determined. Beclin 1 was upregulated in 74 (63.2%) PDAC, 26 (60.5%) SPN, and 14 (43.8%) CP cases. Bcl-2 was upregulated in 38 (32.5%) PDAC, 11 (25.6%) SPN and 24 (75.0%) CP cases. High Beclin 1 and low Bcl-2 expression was significantly correlated with poor differentiation and distant metastasis in PDAC, and associated with the presence of nuclear pleomorphism in SPN and with advanced Tumor-Node-Metastasis stage in PDAC. Beclin 1 and Bcl-2 levels were inversely correlated in PDAC, whereas they were positively correlated in SPN. Low Beclin 1 and high Bcl-2 expression was associated with improved disease-free survival and overall survival (OS). However, the association of Beclin 1 with survival was not significant in the Cox analysis, whereas Bcl-2 expression was significantly correlated with OS in the multivariate analysis. In conclusion, Beclin 1 upregulation exacerbated the progression and aggressiveness of pancreatic neoplasms, and Bcl-2 downregulated expression was an independently poor prognostic factor for PDAC.
在多种人类肿瘤中已发现Beclin 1和B细胞淋巴瘤-2（Bcl-2）的异常表达；然而，关于胰腺肿瘤的相关信息却很少。本研究分析了Beclin 1和Bcl-2在胰腺导管腺癌（PDAC）和胰腺实性假乳头状肿瘤（SPN）中的表达，并评估了它们对PDAC的预后意义。本研究纳入了117例PDAC、43例SPN和32例慢性胰腺炎（CP）病例。通过免疫组织化学半定量评估Beclin 1和Bcl-2的表达水平，并确定它们与PDAC患者生存率的相关性。在74例（63.2%）PDAC、26例（60.5%）SPN和14例（43.8%）CP病例中Beclin 1表达上调。在38例（32.5%）PDAC、11例（25.6%）SPN和24例（75.0%）CP病例中Bcl-2表达上调。在PDAC中，Beclin 1高表达和Bcl-2低表达与低分化和远处转移显著相关，在SPN中与核多形性的存在相关，在PDAC中与肿瘤-淋巴结-转移晚期相关。在PDAC中，Beclin 1和Bcl-2水平呈负相关，而在SPN中呈正相关。Beclin 1低表达和Bcl-2高表达与无病生存期和总生存期（OS）的改善相关。然而，在Cox分析中Beclin 1与生存率的相关性不显著，而在多变量分析中Bcl-2表达与OS显著相关。总之，Beclin
